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Background and purpose: Depressed mood is a common psychiatric problem
associated with Parkinson’s disease (PD), and studies have suggested a benefit
of rasagiline treatment.
Methods: ACCORDO (see the Appendix) was a 12-week, double-blind, pla-
cebo-controlled trial to evaluate the effects of rasagiline 1 mg/day on depres-
sive symptoms and cognition in non-demented PD patients with depressive
symptoms. The primary efficacy variable was the change from baseline to week
12 in depressive symptoms measured by the Beck Depression Inventory (BDI-
IA) total score. Secondary outcomes included change from baseline to week
12 in cognitive function as assessed by a comprehensive neuropsychological
battery; Parkinson’s disease quality of life questionnaire (PDQ-39) scores;
Apathy Scale scores; and Unified Parkinson’s Disease Rating Scale (UPDRS)
subscores.
Results: One hundred and twenty-three patients were randomized. At week 12
there was no significant difference between groups for the reduction in total
BDI-IA score (primary efficacy variable). However, analysis at week 4 did show
a significant difference in favour of rasagiline (marginal means difference  SE:
rasagiline 5.46  0.73 vs. placebo 3.22  0.67; P = 0.026). There were no
significant differences between groups on any cognitive test. Rasagiline signifi-
cantly improved UPDRS Parts I (P = 0.03) and II (P = 0.003) scores versus
placebo at week 12. Post hoc analyses showed the statistical superiority of ra-
sagiline versus placebo in the UPDRS Part I depression item (P = 0.04) and
PDQ-39 mobility (P = 0.007) and cognition domains (P = 0.026).
Conclusions: Treatment with rasagiline did not have significant effects versus
placebo on depressive symptoms or cognition in PD patients with moderate
depressive symptoms. Although limited by lack of correction for multiple
comparisons, post hoc analyses signalled some improvement in patient-rated
cognitive and depression outcomes.
Introduction
Depressed mood is one of the most common psychiat-
ric problems associated with Parkinson’s disease (PD),
affecting up to 50% of PD patients [1,2]. Even in
patients with early disease, the presence of depressed
mood has been found to be a significant predictor of
more impairment in activities of daily living (ADLs)
and increased need for symptomatic therapy of PD
[3]. Although there have been positive studies [4],
treatment with classic antidepressants has not been
found to be consistently effective versus placebo in
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clinical trials [5,6]. It is thought that depression in PD
arises from a complex interaction of psychological
and neuropathological factors. There is some evidence
that the type of depression in PD is distinct from
non-parkinsonian depression. The prevalence of
depression is higher in PD patients than in other simi-
larly disabled patients [7], and it has been suggested
that PD patients have comparatively higher rates of
anxiety and pessimism, and less guilt and self-
reproach [8,9]. Clinically, depressed mood may fluctu-
ate with motor function, improving during the ‘on’
state and worsening during the ‘off’ state [10].
Increasing evidence from epidemiological studies
indicates that depression also affects cognition and is
a risk factor for dementia. Cognitive impairment is
also common in PD and includes impairments in
attention encoding memory and visuospatial and exec-
utive dysfunctions [11], the latter being mainly attrib-
uted to the disruption of the fronto-striatal circuitry.
The clinical efficacy of rasagiline is well established
[12]. In the ADAGIO study, treatment with rasagiline
was reported to improve mood symptoms on the non-
motor experiences of daily living [13,14]. In addition,
results from a small randomized, double-blind, pla-
cebo-controlled study have also suggested that rasagi-
line may exert beneficial effects on attention and
executive abilities in non-demented PD patients with
cognitive impairment [15]. The aims of this random-
ized controlled study were to evaluate the potential
beneficial effect of rasagiline 1 mg/day on depressive
symptoms and to explore the relationship of depres-
sive symptoms with cognitive function in idiopathic
PD patients without dementia.
Methods
Study setting and trial registration
This was a 12-week, randomized, double-blind, pla-
cebo-controlled trial of rasagiline 1 mg/day in PD
patients with depression. The study was conducted
from 5 March 2010 to 2 July 2012 at 12 university
hospitals or Parkinson centres in Italy. It was con-
ducted in accordance with Good Clinical Practice
guidelines and was approved by appropriate institu-
tional review boards; all patients provided written
informed consent to participate. The study is regis-
tered with the European Clinical Trials Database
(EUDRA-CT number: 2009-011144-19).
Study population
Key inclusion criteria were diagnosis of PD (at least
two of three cardinal signs – resting tremor, bradyki-
nesia, rigidity – and no other known or suspected
cause of parkinsonism), age ≥40 and <80 years, and
HoehnYahr stage ≥1 and ≤3 (on treatment). Eligible
patients had a Beck Depression Inventory (version
BDI-IA) score ≥15 and should have been under stable
(4 weeks prior to baseline) dopaminergic treatment.
All stable doses of dopamine receptor agonists, levo-
dopa/carbidopa, levodopa/benserazide and catechol-
O-methyl transferase (COMT) inhibitors were permit-
ted.
This study was specifically designed to be conducted
in PD patients with a stable motor component, and
thus patients with motor fluctuations (the presence of
which may be associated with mood) were excluded
from the study. Other key exclusion criteria included
previous deep brain stimulation surgery; Mini-Mental
State Examination <26; a diagnosis of current or a
history of major depressive episode according to the
Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition, Text Revision (DSM-IV-TR) crite-
ria within 1 year before recruitment into the study;
and presence of psychotic symptoms, e.g. hallucina-
tion and delirium. Treatment with antidepressants, an-
tipsychotics, cholinesterase inhibitors, memantine,
amantadine, anticholinergics, and the hypnotics zalep-
lon, zolpidem, zopiclone and antihistamines were not
allowed and must have been discontinued at least
4 weeks prior to study initiation. Patients currently or
previously treated with selegiline (<90 days prior to
randomization) were also excluded.
Study design
Patients underwent screening and baseline assessments
at visits 1 and 2 and those who met eligibility criteria
were randomized 1:1 to the addition of rasagiline
1 mg/day or matching placebo according to a com-
puter-generated randomization list. Site personnel,
patients and sponsor were blinded to treatment assign-
ment. Subsequent study visits were undertaken at
weeks 4 (visit 3) and 12 (visit 4; study end). In addition,
there was a safety follow-up visit at week 14.
Outcome measures
Evaluations of depressive symptoms (BDI-IA) were
performed at baseline, week 4 and week 12 (study
completion). Cognitive functions (cognitive test bat-
tery) and Apathy Scale (AS) were assessed at baseline
and week 12. The cognitive test battery included the
noun and verb naming tasks of the Aphasia Neuro-
psychological Examination (Esame Neuropsicologico
per l’Afasia in Italian); Trail Making Test, parts A
and B; Cognitive Performance Test for letters and
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categories; Color Naming, Word Reading and Inter-
ference Task of the Stroop Test; Clock Drawing Test;
immediate and delayed recall of the Rey Auditory
Verbal Learning Test; Benton Judgment of Line Ori-
entation Test; and the copy task of the Rey–Osterrieth
Complex Figure test. The Parkinson’s disease quality
of life questionnaire (PDQ-39) and Unified Parkin-
son’s Disease Rating Scale (UPDRS) Parts IIV were
assessed at baseline and week 12, with additional
assessments of UPDRS Parts II (ADL) and III
(Motor) at week 4. All assessments were performed in
the morning, preferably 2 h after the intake of the
morning dose of study medication. All evaluations,
with the exception of motor function (assessed by neu-
rologists), were performed by a psychologist, neuro-
psychologist or physician with adequate experience.
Treatment-emergent adverse events (TEAEs) were
recorded throughout the study.
Statistical analyses
The primary efficacy variable was the change from
baseline to week 12 in depressive symptoms measured
by the BDI-IA total score. The primary efficacy analy-
sis was performed on the full-analysis set (FAS)
(defined as all randomized patients who took at least
one dose of study medication and who had at least
one valid post-baseline assessment of the primary effi-
cacy variable). For the primary efficacy end-point,
and whenever applicable for the secondary efficacy
end-points, the ‘last observation carried forward’ tech-
nique was used to handle missing data. Comparisons
between the two groups were subjected to an analysis
of covariance (ANCOVA) method, fitting the baseline
value of BDI-IA as covariate and treatment as a fixed
factor. Baseline and safety outcomes were assessed
using the safety population, which included all
patients who took at least one dose of study drug.
Secondary efficacy outcomes were analysed in the
same way as the primary outcome variable and
included change from baseline to week 12 in cognitive
function as assessed by the neuropsychological bat-
tery; PDQ-39 scores; AS scores; and UPDRS Parts II
and III subscores.
Post hoc analyses were made for the change from
baseline to week 12 in UPDRS Part I (mental) items
and PDQ-39 domain scores (eight domains).
Determination of sample size
Based on experience in another PD study [16] and
expert opinion, a total sample of 61 evaluable patients
in each arm was calculated to provide 80% power to
detect a minimum difference of 3.3 points in BDI-IA
total score at the 5% two-sided significance level,
assuming a standard deviation of 6.4.
Results
Patient disposition
One hundred and twenty-three patients were enrolled
and randomized in the study (Fig. 1; Table 1). Seven
patients were randomized but did not have a valid
post-baseline assessment of the primary efficacy vari-
able. The safety population included 123 (100.0%)
patients and the FAS included 116 (94.3%) patients.
A total of 106 (86.2%) patients completed the study.
Figure 1 Patient disposition.
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Demographics, baseline characteristics and
concomitant medications
Patient demographics and baseline PD characteristics
were well matched, with no significant differences
between groups (P > 0.05 for all) (Table 1).
Efficacy
After 4 weeks of treatment, there was a significant dif-
ference between the BDI-IA total score reduction
from baseline between groups (marginal means differ-
ence  SE: rasagiline 5.46  0.73 vs. placebo
3.22  0.67; P = 0.026). However, after 12 weeks of
treatment (primary efficacy end-point) there was no
significant difference between groups (marginal means
difference  SE: rasagiline 5.40  0.79 vs. placebo
4.43  0.73; P = 0.368). Figure 2 shows that the
response to rasagiline remained stable from week 4
but there was an improvement with placebo.
After 12 weeks of treatment there were no signifi-
cant differences between groups on any of the individ-
ual cognitive tests contained within the battery
(Table 2).
Treatment with rasagiline significantly improved
UPDRS Part II scores versus placebo at week 12
(marginal means difference  SE: rasagiline
1.37  0.35 vs. placebo 0.06  0.32; P = 0.003).
There was no significant effect of treatment on UP-
DRS Part III subscores (rasagiline 0.88  0.56 vs.
placebo 0.42  0.51; P = 0.090). There was a signifi-
cant difference between groups on UPDRS Part I sub-
scores (rasagiline 0.96  0.16 vs. placebo
0.49  0.15; P = 0.030) (Table 3). Post hoc analysis
of individual UPDRS Part I items also found a signif-
icant between-group difference for depression (rasagi-
line 0.59  0.09 vs. placebo 0.28  0.08;
P = 0.041). There were no significant differences in
other individual UPDRS Part I items.
There was no significant effect of treatment on
PDQ-39 total scores (rasagiline 6.28  2.24 vs. pla-
cebo 0.73  2.06; P = 0.074). However, a post hoc
analysis of PDQ-39 domains found significant differ-
ences favouring rasagiline in PDQ-mobility scores
(P = 0.007) and PDQ-cognition scores (P = 0.026)
(Table 4). No significant between-group differences
were noted for apathy as assessed by the AS.
Safety
A total of 15 vs. 17 patients (rasagiline versus placebo
group, respectively) reported at least one TEAE; most
TEAEs were mild or moderate. No TEAE was
reported more than two times in either group. Two
patients in the rasagiline group (radius fracture;
melanocytic nevus) and one in the placebo group
Figure 2 BDI-IA total score change from baseline.
Table 1 Demographics and baseline disease characteristics (safety
population)
Parameter (safety population)
Rasagiline
(N = 58)
Placebo
(N = 65)
Male gender, n (%) 27 (46.6%) 38 (58.5%)
Age (years), mean  SD 66.0  8.74 66.1  8.35
Number of years in
education, mean  SD
9.1  4.33 9.6  4.49
Duration of PD
(years), mean  SD
3.7  3.17 4.8  3.78
Hoehn and Yahr staging, n (%)
Stage 1 9 (15.5%) 9 (13.8%)
Stage 1.5 12 (20.7%) 11 (16.9%)
Stage 2 29 (50.0%) 34 (52.3%)
Stage 2.5 5 (8.6%) 6 (9.2%)
Stage 3 3 (5.2%) 5 (7.7%)
BDI-IA score,
mean  SD
20.2  5.34 20.1  6.56
MMSE, mean  SD 28.7  1.96 28.8  1.21
Current PD
medications, n (%)
Levodopa 36 (62.1%) 45 (69.2%)
Levodopa/
carbidopa/entacapone
5 (8.6%) 14 (21.5%)
Me-levodopa 7 (12.1%) 4 (6.2%)
Ropinirole 9 (15.5%) 8 (12.3%)
Pramipexole 19 (32.8%) 31 (47.7%)
Rotigotine 5 (8.6%) 3 (4.6%)
Entacapone 2 (3.4%) –
PD, Parkinson’s disease; BDI-IA, Beck Depression Inventory;
MMSE, Mini-Mental State Examination.
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(polyneuropathy in malignant disease and respiratory
disorder) reported a serious TEAE. Four patients in
the rasagiline group withdrew due to an TEAE
(aggravated dyskinesia, vertigo, left trunk flexion due
to PD, nausea) versus none in the placebo group.
Discussion
To the best of our knowledge this is the first prospec-
tive study exploring the efficacy of rasagiline versus
placebo on depressive symptoms in PD. The primary
end-point, change from baseline to week 12, was not
achieved although a significant difference favouring
rasagiline was observed at 4 weeks. Likewise, the pre-
planned analyses did not find any significant differ-
ences in cognitive function.
One potential reason for the lack of efficacy on
depressive symptoms may be the BDI-IA inclusion
criteria, which selected patients with at least a moder-
ate severity of depressive symptoms (baseline BDI-IA
scores were 20 in both groups). It may be that the
effects of simply enhancing the dopaminergic system
by inhibiting dopamine metabolism are not enough to
treat moderate to severe depressive symptoms. The
only antiparkinsonian therapy that has been shown in
a randomized controlled trial to improve depressive
symptoms in PD is pramipexole (patients in the pram-
ipexole trial had milder baseline BDI scores of 18.7–
19.5) [16], which has been shown to bind with high
affinity to dopamine D3 receptors in the prefrontal
cortex, amygdala, and medial and lateral thalamus
(all known to have some relation to depression) [17].
In addition, the improvement in depressive sympto-
mology in the placebo group between weeks 4 and 12
probably reflects the positive influence of being in a
study for depression (e.g. increased contact with
Table 2 Cognitive battery scores
Variable
(FAS
population)
Baseline score
(mean  SD)
Change from
baseline at week 12
(mean  SD)
Language
ENPA
Placebo 17.90  3.23 (n = 63) 0.44  2.85 (n = 61)
Rasagiline 17.03  4.37 (n = 53) 0.68  2.85 (n = 52)
Memory
RAVLT immediate recall
Placebo 34.49  37.59 (n = 63) 1.58  38.51 (n = 60)
Rasagiline 36.85  11.75 (n = 53) 2.27  10.79 (n = 52)
RAVLT delayed recall
Placebo 6.57  3.34 (n = 63) 1.21  2.53 (n = 61)
Rasagiline 7.13  3.65 (n = 53) 0.92  2.27 (n = 52)
Attention
Word reading Stroop test
Placebo 48.10  17.85 (n = 62) 0.92  13.64 (n = 60)
Rasagiline 46.08  18.48 (n = 53) 1.29  9.57 (n = 52)
Color naming Stroop test
Placebo 31.37  13.89 (n = 62) 0.32  9.71 (n = 60)
Rasagiline 31.87  9.94 (n = 53) 1.65  5.85 (n = 52)
Trails A
Placebo 68.97  53.32 (n = 63) 7.78  46.81 (n = 59)
Rasagiline 58.31  30.17 (n = 52) 1.10  17.40 (n = 51)
Frontal functions
Trails B
Placebo 160.09  97.02 (n = 54) 4.28  70.04 (n = 50)
Rasagiline 157.87  86.75 (n = 47) 4.22  53.03 (n = 46)
Trails BA
Placebo 99.56  77.03 (n = 54) 6.24  69.34 (n = 50)
Rasagiline 100.79  82.32 (n = 47) 3.50  48.63 (n = 46)
Stroop test non-congruent correct answers
Placebo 17.41  13.21 (n = 61) 0.58  13.18 (n = 59)
Rasagiline 17.10  7.47 (n = 52) 0.39  4.30 (n = 51)
Clock Drawing Test
Placebo 8.97  10.19 (n = 63) 0.63  12.88 (n = 59)
Rasagiline 6.88  3.44 (n = 53) 0.33  3.40 (n = 52)
CPT for letter
Placebo 27.00  11.45 (n = 63) 0.36  7.18 (n = 61)
Rasagiline 29.13  14.44 (n = 53) 2.12  9.35 (n = 52)
CPT for categories
Placebo 22.40  15.10 (n = 63) 0.62  6.85 (n = 61)
Rasagiline 22.28  14.46 (n = 52) 1.71  10.86 (n = 50)
Visuospatial function
BJLOT
Placebo 19.38  7.50 (n = 63) 0.84  7.18 (n = 61)
Rasagiline 21.85  8.40 (n = 52) 0.98  3.73 (n = 51)
ROCF copy
Placebo 26.83  12.23 (n = 63) 0.07  11.21 (n = 56)
Rasagiline 28.50  6.84 (n = 52) 1.13  6.88 (n = 51)
FAS, full-analysis set; ENPA, Aphasia Neuropsychological Exami-
nation (Esame Neuropsicologico per l’Afasia in Italian); RAVLT,
Rey Auditory Verbal Learning Test; Trails, Trail Making Test, parts
A and B; CPT, Cognitive Performance Test for letters and catego-
ries; BJLOT, Benton Judgment of Line Orientation Test; ROCF,
Rey–Osterrieth Complex Figure test.
Table 3 Change from baseline in UPDRS subdomains
Variable
(FAS
population)
Baseline score
(mean  SD)
Change from
baseline at week 12
(marginal mean  SE)
Subdomains of UPDRS
Mentation
Placebo 0.37  0.52 (N = 63) 0.04  0.05 (N = 60)
Rasagiline 0.38  0.53 (N = 52) 0.09  0.06 (N = 52)
Thought disorder
Placebo 0.27  0.48 (N = 63) 0.04  0.04 (N = 60)
Rasagiline 0.17  0.43 (N = 52) 0.07  0.05 (N = 52)
Depression
Placebo 1.68  0.74 (N = 63) 0.28  0.08 (N = 60)
Rasagiline 1.56  0.70 (N = 52) 0.59  0.09* (N = 52)
Motivation/initiative
Placebo 1.13  0.87 (N = 63) 0.07  0.08 (N = 60)
Rasagiline 1.06  0.94 (N = 52) 0.33  0.09 (N = 52)
UPDRS, Unified Parkinson’s Disease Rating Scale; FAS, full-analy-
sis set.
*Significant difference.
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healthcare professionals and expectations of improve-
ment) [18].
By contrast, post hoc analysis of the UPDRS Part
I did show a significant effect on the depression
item. This probably reflects the less comprehensive
assessment of depressive symptoms by just one item
versus a 21-item questionnaire specifically designed
to assess depression. Interestingly, the ADAGIO
delayed-start study, which was conducted in patients
with early PD and included an assessment of non-
motor experiences of daily living (nM-EDL) in the
placebo-controlled phase, also found that treatment
with rasagiline 1 mg/day significantly improved the
depression item versus placebo. Although baseline
depression was not specifically assessed in ADA-
GIO, baseline nM-EDL scores were low suggesting
that patients had less severe symptoms [13,14]. More
recently, an analysis of the 191 ADAGIO patients
who were concomitantly treated with antidepressants
found that depression and cognition item scores
improved significantly in the rasagiline group com-
pared with the placebo group [19]. Importantly, the
effect on depressive symptoms remained significant
after controlling for motor change, thereby confirm-
ing some sort of role for the dopamine system in
depression in PD.
Taken together, the secondary efficacy results do
not show a clear effect of rasagiline on cognitive func-
tion. Thus far, only one small study has been pub-
lished exploring the efficacy of rasagiline on cognitive
function [15]. This study conducted in 55 PD patients
found that rasagiline provides significant improve-
ments in attention (as measured by digit span) and
executive functions (as measured by verbal fluency).
However, the study specifically excluded patients with
a geriatric depression scale score >13, thereby exclud-
ing patients with all but the mildest depressive symp-
toms. The discordance between the results of the
earlier study and ours might reflect different method-
ologies used to assess cognitive functions and different
sizes in PD samples.
As with other studies, treatment with rasagiline
improved both UPDRS mental and ADL scores
[12]. The effects on motor function did not reach
statistical significance but all patients already had a
stable motor component and there was no require-
ment for additional therapy. Although improvements
in ADL are mostly driven by motor function, they
are derived from the patients self-report over the
past week and also include non-motor aspects of
the disease. From the patients’ perspective, overall
quality of life (as self-reported using the PDQ-39)
was not found to significantly improve with rasagi-
line, but patients were able to identify improvements
in mobility and in cognition. The improvement of
the PDQ-mobility item is expected because it reflects
the trend towards improvement of UPDRS motor
scores. However, the effects on cognition are not
consistent with the results of objective neuropsycho-
logical results. As already noted, the PDQ-39 is a
self-administered test, and thus the results reflect
patients’ own impressions of their overall cognitive
status versus the very specific cognitive tests
employed in the test battery.
The strengths of this study include its randomized,
placebo-controlled design, prospective nature and its
reasonable size. However, our study has several
important limitations. Patients with milder depressive
symptoms, those already treated with antidepressants
and those with motor fluctuations were excluded
from the study and it was only of a short (12
weeks) duration. Recruitment was slow, and eventu-
ally there were fewer than the estimated 61 patients
in the FAS for the rasagiline group – implying that
the study could be underpowered for testing the pri-
Table 4 Change from baseline in PDQ-39 domains
Variable
(FAS
population)
Baseline score
(mean  SD)
Change from
baseline at week 12
(marginal mean  SE)
Domains of PDQ-39
Mobility
Placebo 35.01  21.44 (N = 62) 2.83  2.33 (N = 59)
Rasagiline 31.37  25.26 (N = 53) 6.28  2.62* (N = 52)
Activities of daily living
Placebo 30.22  22.65 (N = 63) 1.51  2.33 (N = 60)
Rasagiline 24.47  20.13 (N = 53) 3.64  2.62 (N = 52)
Emotional well-being
Placebo 43.16  18.75 (N = 63) 2.33  2.23 (N = 60)
Rasagiline 38.19  19.88 (N = 53) 5.66  2.54 (N = 52)
Stigma
Placebo 32.18  22.59 (N = 61) 0.27  2.54 (N = 58)
Rasagiline 17.46  20.19 (N = 53) 4.58  2.90 (N = 51)
Social support
Placebo 13.45  18.15 (N = 63) 1.03  2.43 (N = 59)
Rasagiline 8.02  12.11 (N = 53) 1.44  2.76 (N = 51)
Cognition
Placebo 28.42  17.91 (N = 61) 2.41  2.03 (N = 59)
Rasagiline 25.47  19.06 (N = 53) 4.00  2.28* (N = 52)
Communication
Placebo 23.55  24.98 (N = 62) 1.53  2.22 (N = 59)
Rasagiline 16.34  20.07 (N = 53) 6.60  2.52 (N = 51)
Bodily discomfort
Placebo 36.90  24.26 (N = 63) 2.72  2.65 (N = 60)
Rasagiline 33.80  23.42 (N = 53) 2.01  2.97 (N = 52)
Total
Placebo 51.65  26.88 (N = 62) 1.03  2.33 (N = 60)
Rasagiline 41.46  23.03 (N = 52) 6.24  2.69 (N = 51)
PDQ-39, Parkinson’s disease quality of life questionnaire; FAS, full-
analysis set.
*Significant difference.
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mary and secondary outcomes. In addition, the large
number of tests (including 13 cognitive tests)
employed meant that there were a high number of
statistical tests with no correction for multiplicity
and the analyses of UPDRS Part I items and PDQ
domains were conducted post hoc. Finally, it should
be noted that, at the time this study was conducted,
the concept of mild cognitive impairment (MCI) in
PD was not universally accepted, and as such no
data were available on the MCI status of patients in
this study. Future studies would need to collect such
MCI data.
In summary, rasagiline was not found to have sig-
nificant effects versus placebo in PD patients with
moderately severe depressive symptoms. However,
post hoc analyses and patient self-reported measures
do appear to signal some improvements in both
depression and cognition. Taken together with the
results of other recently reported analyses [13,19], this
study supports the suggestion that studies in PD
patients with milder depressive symptoms are war-
ranted.
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